| Dr Thomas W Loeb, | |
|
994 5th Ave, New York, NY 10028-0100 | |
| (212) 327-3700 | |
| (212) 327-4506 |
| Full Name | Dr Thomas W Loeb |
|---|---|
| Gender | Male |
| Speciality | Plastic Surgery |
| Location | 994 5th Ave, New York, New York |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013164276 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208200000X | Plastic Surgery | 147494 (New York) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Thomas W Loeb, 994 5th Ave, New York, NY 10028-0100 Ph: (212) 327-3700 | Dr Thomas W Loeb, 994 5th Ave, New York, NY 10028-0100 Ph: (212) 327-3700 |
News Archive
A new microRNA (miRNA) screening assay detected the majority of early-stage colorectal cancers with good specificity and sensitivity. Our test has the potential to be safe, cheap, robust, accurate and of little or no inconvenience to the individual, and could, therefore, easily be integrated into national screening programs as part of an annual checkup,said Søren Jensby Nielsen, Ph.D., scientific manager, Diagnostic Product Development, Exiqon A/S
Yaupon Therapeutics, a privately held specialty pharmaceutical company, today announced positive top-line results from the pivotal multi-center study of its lead product candidate, a proprietary topical mechlorethamine gel for the treatment of early-stage cutaneous T-cell lymphoma (CTCL - stages I-IIa). The top-line data show that the study, which was conducted under a Special Protocol Assessment (SPA), achieved its primary and secondary endpoints.
Today Biogen Idec announced that the U.S. Food and Drug Administration (FDA) has approved two separate dosing innovations designed to improve the treatment experience for patients receiving once-a-week AVONEX for relapsing forms of multiple sclerosis (MS).
Bristol-Myers Squibb Company has announced that the U.S. Food and Drug Administration (FDA) has granted full approval for Sprycel (dasatinib) for the treatment of adults in all phases of chronic myeloid leukemia (CML) (chronic, accelerated, or myeloid or lymphoid blast phase) with resistance or intolerance to prior therapy including Gleevec (imatinib mesylate).
"This tour is a national call to action to achieve these goals and we are delighted to be working with our three partner agencies in Chicago this weekend."
› Verified 1 days ago
Dr. Brad Michael Gandolfi, M.D. Plastic Surgery Medicare: Accepting Medicare Assignments Practice Location: 905 5th Ave Ste 1c, New York, NY 10021 Phone: 212-287-7211 Fax: 212-287-7210 | |
Alexes Hazen, M.D. Plastic Surgery Medicare: Accepting Medicare Assignments Practice Location: 535 5th Ave Fl 29, New York, NY 10017 Phone: 917-301-6563 Fax: 347-407-8652 | |
Dr. Richard James Coburn, DMD MD Plastic Surgery Medicare: Not Enrolled in Medicare Practice Location: 880 Fifth Avenue, New York, NY 10021 Phone: 212-288-5100 Fax: 212-472-2216 | |
Jack Francis Woods, Plastic Surgery Medicare: Not Enrolled in Medicare Practice Location: Mskcc, 1275 York Avenue, New York, NY 10065 Phone: 917-375-5135 | |
Mihye Choi, M.D. Plastic Surgery Medicare: Accepting Medicare Assignments Practice Location: 305 E 47th St, Suite 1a, New York, NY 10017 Phone: 212-263-6004 Fax: 212-263-6319 | |
Dr. Robert Johnson Allen Jr., MD Plastic Surgery Medicare: Accepting Medicare Assignments Practice Location: 1275 York Ave # Mri1007, New York, NY 10065 Phone: 212-639-6131 Fax: 212-717-3677 |